Exosomes derived from gefitinib-treated EGFR-mutant lung cancer cells alter cisplatin sensitivity via up-regulating autophagy. - Wikidata - wikimedia - TriplyDB

Exosomes derived from gefitinib-treated EGFR-mutant lung cancer cells alter cisplatin sensitivity via up-regulating autophagy.

Exosomes derived from gefitinib-treated EGFR-mutant lung cancer cells alter cisplatin sensitivity via up-regulating autophagy.

http://www.wikidata.org/entity/Q37269370

about

MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma Extracellular vesicles for personalized therapy decision support in advanced metastatic cancers and its potential impact for prostate cancer.Extracellular Vesicle Biology in the Pathogenesis of Lung Disease.Exosome is a mechanism of intercellular drug transfer: Application of quantitative pharmacology.[Research Progress of Exosomes in Lung Cancer Diagnosis and Treatment].DSGOST regulates resistance via activation of autophagy in gastric cancer.Exosome-mediated gefitinib resistance in lung cancer HCC827 cells via delivery of miR-21.The roles of tumor-derived exosomes in non-small cell lung cancer and their clinical implications

P2860

Q37709001-1D6DB967-C94D-443D-95C0-CC76CB7B9460 Q38600919-2C7C1ED8-0449-4D98-93F4-C576CABB3198 Q40134679-3059C4C5-8A36-488A-BD92-A5EAFDD3DA08 Q47622996-361709C8-F2F5-4660-AFE4-524AF08CDD7E Q53760783-A7F15FF9-2FBF-4A4F-8809-8D4C9FF1C136 Q54971642-6CFDF4E3-0A62-4FD8-8263-13C990E0F6A3 Q55408017-27040915-497B-4293-9537-71101D09501E Q58741629-4D858EA6-4BFE-4940-B7CC-0C70BCD4E97F

P2860

Exosomes derived from gefitinib-treated EGFR-mutant lung cancer cells alter cisplatin sensitivity via up-regulating autophagy.

http://www.wikidata.org/entity/Q37269370

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 25 March 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Exosomes derived from gefitini ...... y via up-regulating autophagy.

@en

Exosomes derived from gefitini ...... y via up-regulating autophagy.

@nl

type

label

Exosomes derived from gefitini ...... y via up-regulating autophagy.

@en

Exosomes derived from gefitini ...... y via up-regulating autophagy.

@nl

prefLabel

Exosomes derived from gefitini ...... y via up-regulating autophagy.

@en

Exosomes derived from gefitini ...... y via up-regulating autophagy.

@nl

P1433

Q37269370-D53931AF-8A69-473F-84C4-200C5946074D

P1476

Q37269370-710EBBB3-7A6F-471E-813D-7DA78764CF59

P2093

Q37269370-0C1BCD7E-7A20-4FAA-8D4D-93B71ABE1F72

Q37269370-65F9A9CD-97BA-4C0B-ACB8-8106412D8896

Q37269370-A040AA7D-B447-4531-8200-467D63DD7263

Q37269370-A32C77A7-466F-48C1-8E39-49297AFB139C

Q37269370-A3DAF29D-2612-4413-BCB7-112961DA4FC6

Q37269370-A3FA1EFE-5B4F-40F3-B743-31E451E99DDB

Q37269370-A96F41AC-7B36-4C34-BA17-9A7E3BDD66C3

Q37269370-BAAA0C74-7DB8-4A2B-A8AC-E7DF6DB2E25F

Q37269370-CDF12D11-4391-4CF8-942F-D84E9A13A7DF

Q37269370-D650B124-C48C-4410-A226-3F1BC70A5F17

P2860

Q37269370-09433522-D324-4838-A0C7-D9B3AD762CBD

Q37269370-0BA38B27-3F4C-4467-B96E-3815915BF47B

Q37269370-15E56643-8875-451D-BB25-A6E890910B49

Q37269370-1EE60FBD-F59E-4BA9-8329-820E5F9E0B16

Q37269370-2011A2D2-6FAC-42A5-B829-F27E4CCB901A

Q37269370-25FF1955-74E8-47E7-B04F-4CDADF5E4856

Q37269370-381AEEDC-7025-49E4-9606-06DD829C3A52

Q37269370-41474391-A473-4693-93EC-9885E39567CF

Q37269370-414B1C14-612B-4711-8A7A-5DC73935E114

Q37269370-44FFFC60-1D57-4CAC-8D7B-933DCE01FBF7

P304

Q37269370-03DF17C9-2A51-4433-B13D-F226C6043A72

P31

Q37269370-6D0E920D-2148-4CCF-BE10-CBECA76362FB

P356

Q37269370-E641E401-9181-4EDD-8F2F-B1026DF133B6

P407

Q37269370-F3E93EB7-7D28-46E2-8D72-2B011C6D1745

P433

Q37269370-C20CB511-FA3B-4508-9C18-4E90D8A9C699

P478

Q37269370-53B05637-B613-4BB9-8F01-BCAC9DA1EE7C

P577

Q37269370-DB79678E-0E8F-4AA8-A312-7DDC4B716490

P5875

Q37269370-2F97C4E4-FBAF-4471-AFAC-93FB5B2120EA

P698

Q37269370-E9868272-D2BA-4010-A385-A5F711BD9D8F

P921

Q37269370-915FD0A4-6467-4B82-8A53-1ABA7B36024C

P932

Q37269370-9B627DFD-9242-45E0-B041-264D0611552C

P356

ONCOTARGET.8358

P1433

P1476

Exosomes derived from gefitini ...... y via up-regulating autophagy.

@en

P2093

Fang Wang

http://www.w3.org/2001/XMLSchema#string

Guo-Ping Sun

http://www.w3.org/2001/XMLSchema#string

Han-Qing Yu

http://www.w3.org/2001/XMLSchema#string

Hua Wang

http://www.w3.org/2001/XMLSchema#string

Jia-Tao Liu

http://www.w3.org/2001/XMLSchema#string

Jian Gao

http://www.w3.org/2001/XMLSchema#string

Liang Cheng

http://www.w3.org/2001/XMLSchema#string

Lu-Lu Fan

http://www.w3.org/2001/XMLSchema#string

Wei Wei

http://www.w3.org/2001/XMLSchema#string

Xiao-Qiu Li

http://www.w3.org/2001/XMLSchema#string

P2860

Exosomes reflect the hypoxic status of glioma cells and mediate hypoxia-dependent activation of vascular cells during tumor development

Isolation and characterization of exosomes from cell culture supernatants and biological fluids

Exosomes--vesicular carriers for intercellular communication

Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.

Interactions between exosomes from breast cancer cells and primary mammary epithelial cells leads to generation of reactive oxygen species which induce DNA damage response, stabilization of p53 and autophagy in epithelial cells.

Expulsion of small molecules in vesicles shed by cancer cells: association with gene expression and chemosensitivity profiles.

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

Docetaxel-resistance in prostate cancer: evaluating associated phenotypic changes and potential for resistance transfer via exosomes.

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

P304

24585-24595

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.8358

http://www.w3.org/2001/XMLSchema#string

P407

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2016-03-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

299434183

http://www.w3.org/2001/XMLSchema#string

P698

27029054

http://www.w3.org/2001/XMLSchema#string

P921

P932

5029725

http://www.w3.org/2001/XMLSchema#string